Eugeni Domènech ¹, Julián Panés ², Joaquín Hinojosa ³, Vito Annese ⁴, Fernando Magro ⁵, Giacomo Carlo Sturniolo ⁶, Fabrizio Bossa ⁷, Francisco Fernández ⁸, Benito González-Conde ⁹, Valle García-Sánchez ¹⁰, Axel Dignass ¹¹, José Manuel Herrera ¹², José Luis Cabriada ¹³, Jordi Guardiola ¹⁴, Maurizio Vecchi ¹⁵, Francisco Portela ¹⁶, Daniel Ginard ¹⁷, J Crohns Colitis. 2018 May 25;12(6):687-694.

In a randomized trial, the addition of 7 weekly sessions of GMA to a conventional course of oral prednisone did not increase the proportion of steroid-free remissions in patients with active steroid-dependent UC, though it delayed clinical relapse.

https://pubmed.ncbi.nlm.nih.gov/29490024/

Takayuki Yamamoto ¹, Toshiaki Tanaka ², Tadashi Yokoyama ³, Takahiro Shimoyama ¹, Hiroki Ikeuchi ⁴, Motoi Uchino ⁴, Toshiaki Watanabe ⁵ , Therap Adv Gastroenterol. 2017 Feb;10(2):199-206.

GMA has a good safety profile, but its efficacy appears to be limited in the management of chronic refractory pouchitis. However, a large controlled study should be conducted to evaluate the efficacy of GMA therapy in patients with pouchitis at an earlier clinical stage, before the disease has become refractory to conventional medical therapy.

https://pubmed.ncbi.nlm.nih.gov/28203278/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298477/pdf/10.1177_1756283X16679348.pdf